Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)).
Psychiatric treatment requires the use of drugs which are in many cases associated with severe side effects and inadequate response. In the past decade extensive research has investigated the link between gene alterations and treatment response and several strong associations have been reported. The identification of genes influencing treatment outcome will facilitate the pre-treatment selection of the most beneficial drug according to an individual's pharmacogenetic profile. Recent advances indicate that this goal is achievable in the near future. The scope of this communication is to review all the recent findings in psychopharmacogenetics leading to the individualization of treatment.
Arranz
M J
MJ
Clinical Neuropharmacology, Institute of Psychiatry, London SE5 8AF, UK. m.arranz@iop.kcl.ac.uk
Mancama
D
D
Kerwin
R W
RW
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D014644:Genetic Variation; D006801:Humans; D011110:Polymorphism, Genetic; D011618:Psychotic Disorders / Q000188:drug therapy / Q000235:genetics; D017981:Receptors, Neurotransmitter / Q000235:genetics*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D017981:Receptors, Neurotransmitter; D003577:Cytochrome P-450 Enzyme System